← Eichor
Study identifier: NCT07542808 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

An Open-Label, Double-Treatment Group Study to Evaluate the Efficacy and Safety of Human Allogeneic Bone-Marrow- Derived Mesenchymal Stromal Cell Product StromaForte Compared With Hyaluronic Acid for the Treatment of Knee Osteoarthritis

Condition: Knee Arthritis Osteoarthritis  ·  Sponsor: Cellcolabs Clinical SPV Limited

PhasePhase 2/Phase 3
Planned participants140
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

StromaForte injection for knee OA

This description comes directly from the study's public registry record.

Talk to the study team

Bahar Kasaei  ·  +971506845410  ·  hello@cellcolabs.com

Always discuss trial participation with your own doctor first.

Locations (1)

Burjeel Medical CityAbu Dhabi, United Arab EmiratesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07542808